SCRI Development Innovations
As of the edition of 20 October 2026, SCRI Development Innovations runs 24 drugs, 10 of them marketed; it is on route A at 7 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 10 |
| Active | 5 |
| Went quiet | 5 |
| Stopped | 3 |
| Status not established | 1 |
| Total | 24 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Bevacizumab | Ends 2027 (orphan exclusivity) | 2 |
| Erlotinib | none listed | 2 |
| Pertuzumab | Ended 2024 (reference-product exclusivity) | 0 |
| Pomalidomide | Ends 2031 (patent) | 0 |
| Pazopanib | none listed | 5 |
| Panobinostat | Ends 2028 (patent) | 0 |
| Duvelisib | Ends 2032 (patent) | 2 |
| Capmatinib | Ends 2032 (patent) | 1 |
| Ixazomib citrate | Ends 2029 (patent) | 0 |
| Vinflunine | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 7 targets, route B at 0 targets.
All 7 rows on route A or B
In the product7 company-target rows on route A or B; 4 are not shown here, and no score is.
See all 7 targets where SCRI Development Innovations needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.